<DOC>
	<DOCNO>NCT01065246</DOCNO>
	<brief_summary>This phase II single arm , open-label study investigate safety second cycle catumaxomab patient malignant ascites due carcinoma , require first therapeutic puncture treatment CASIMAS study .</brief_summary>
	<brief_title>Safety Study Second Intraperitoneal ( I.P . ) Infusion Cycle Catumaxomab Patients With Malignant Ascites</brief_title>
	<detailed_description>Up 30 evaluable patient CASIMAS study enrol . Catumaxomab infuse intraperitoneally 3hour constant-rate infusion 4 time within 11 day ascend dosage ( 10 - 20 - 50 - 150 Âµg ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>patient complete 4 infusion catumaxomab CASIMAS study age &gt; = 18 year Karnofsky index &gt; = 60 % patient malignant ascites require first therapeutic ascites paracentesis least 60days follow last catumaxomab infusion CASIMAS study Patients standard therapy either available longer feasible acute chronic infection concomitant treatment investigational product catumaxomab , cancer , chemo radiotherapy previous treatment entirely murine monoclonal antibody catumaxomab liver metastasis volume &gt; 70 % liver metastasize tissue</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>malignant ascites</keyword>
	<keyword>second cycle</keyword>
	<keyword>trifunctional</keyword>
</DOC>